REFERENCES
- Grillo-Lopez AJ. Cancer therapies crisis in the USA. Expert Rev Anticancer Ther. 3(5), 579–582 (2003).
- Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. Clin. Oncol 21,1404–1411 (2003).
- Code of Federal Regulations. Establishment of Standing Technical Advisory Committees for Human Prescription Drugs, Title 21, Volume 1, Part 14, Subpart I, Section 14.160 (2003).
- Grillo-Lopez AJ. Rituximab: an insider'shistorical perspective. Semin. Oncol 27(6 Suppl. 12), 9–16 (2000).
- Grillo-Lopez AJ. Rituximab: the first decade (1993–2003). Expert Rev. Anticancer Ther. 3(6), 767–779 (2003).
- Grillo-Lopez AJ. Rituximab: clinical development of the first therapeutic antibody for cancer. In: Applications of Pharmaceutical Biotechnology a Comprehensive Textbook. Kayser O, Muller R (Eds), Wiley-VCH Verlag, Weinheim, Germany, 205–221 (2003).
Website
- Advisory committee industry representatives www.fda.gov/oc/advisory/industry.htlm (Accessed September 2004)